3 Matching Annotations
  1. Mar 2021
  2. Local file Local file
    Untitled document
    1
    1. alexandra.p 19 Mar 2021

      Smith, P. (2021). Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. WHO.

      is:pdf lang:en COVID-19 vaccine Oxford AstraZeneca interim guidance WHO SAGE recommendation clinical trial efficacy interdose interval

    Tags

    Annotators

  3. Feb 2021
  4. www.who.int www.who.int
    Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca
    1
    1. zoe_ikeotuonye 16 Feb 2021

      Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. (n.d.). Retrieved 16 February 2021, from https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1

      lang:en COVID-19 is:article advice immunization interim guidance vaccine Oxford University SAGE vaccination pandemic critical preparedness readiness response interim guidance
    Visit annotations in context

    Tags

    Annotators

    URL

    who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1
  5. Jan 2021
  6. www.nejm.org www.nejm.org
    Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM
    1
    1. marta_radosevic 20 Jan 2021

      Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

      is:article lang:en interim result trial clinical trial vaccine COVID-19 SARS safety Janssen NEJM
    Visit annotations in context

    Tags

    Annotators

    URL

    nejm.org/doi/full/10.1056/NEJMoa2034201